Leading the Way in Cancer Research and Care
We are devoted to crushing cancer here in our community and worldwide. Our experts—visionary cancer researchers, the very best clinicians and highly trained team members—can provide treatments that others can’t, including improved access to clinical trials, precision-guided radiation therapy, and non-invasive immunotherapies.
Our Impact
Since the beginning of the Hope to Health Campaign in July 2015, gifts large and small have supported cancer care and research in many ways.
4000+
new cancer cases treated each year
250+
ACTIVE clinical cancer trials
$91M
FOR CANCER CARE ACROSS ALL FOUR PRIORITIES
Impact Stories
The Next Frontier in Pediatric Cancer Research
In order to advance their vision of a world free of pediatric cancer, the MACC Fund made a $25 million commitment to MCW and Children’s Wisconsin to fight cancer and related blood disorders. The pledge, which is the largest in the MACC Fund’s history, extends and enhances the four-decade partnership aimed at advancing hope and lifesaving solutions for kids and their families.
Most recently termed the “The Next Frontier in Pediatric Cancer Research,” the powerful partnership will accelerate the next revolution in cellular therapies, translational research for more treatment options, expanded clinical trials, and the best clinical outcomes for kids—physically, psychologically, and socially.
In order to advance their vision of a world free of pediatric cancer, the MACC Fund made a $25 million commitment to MCW and Children’s Wisconsin to fight cancer and related blood disorders. The pledge, which is the largest in the MACC Fund’s history, extends and enhances the four-decade partnership aimed at advancing hope and lifesaving solutions for kids and their families.
Most recently termed the “The Next Frontier in Pediatric Cancer Research,” the powerful partnership will accelerate the next revolution in cellular therapies, translational research for more treatment options, expanded clinical trials, and the best clinical outcomes for kids—physically, psychologically, and socially.
Mary Ann and Charles LaBahn, looking to enhance the collaborative power of cancer experts at MCW, made a $3 million gift to name the LaBahn Pancreatic Cancer Research Program. Their philanthropic commitment is already driving an acceleration of novel clinical trials, including a first-ever molecular-profiling study. The LaBahn Program is expanding the research arm of an already world-class program and propelling MCW into an elite group of cancer research institutions with a demonstrated passion, world-class talent, and unwavering commitment to curing this disease. Arlene and Joel Lee’s belief in MCW’s powerful capabilities in cancer research can be traced back to their first gift nearly 22 years ago. Since then, the Lees have supported various areas of cancer science and made a significant gift to establish the Joel and Arlene Lee Endowed Chair in Pancreatic Cancer Research. Their passion for medical research also drives fundraising and awareness for the Department of Surgery’s We Care Fund for Medical Innovation and Research. Arlene founded and chairs the fund’s committee, of which Joel is also a member, and she served as a Hope to Health Campaign Cabinet member.
As distinguished leaders at Froedtert Hospital and MCW, Joan Lubar and Dr. John Crouch along with David and Madeleine Lubar understand fully how academic medicine powers research-based patient care in the region. Joan, David and their families led the way by demonstrating their powerful partnership with a significant gift to establish the Jeffrey C. Siegel Quality of Life Center in the Cancer Center. This gift is dedicated to providing cancer patients and their families with a full range of support services including psych-oncology, nutrition and wellness programs, and financial and genetic counselors, among others.
“
This gift from Mary Ann and Charles is a game-changer for our work in this field—a visionary and timely gift.
SUSAN TSAI, MD, MHS ASSOCIATE PROFESSOR OF SURGERY, FOUNDING DIRECTOR OF THE LABAHN PANCREATIC CANCER PROGRAM